We are live on
!
Find out more
Primecap Management Portfolio holdings
AUM
$169B
Turnover
4.85%
1-Year Est. Return
114.72%
This Fund
S&P 500
This Quarter
Est. Return
-1.54%
1 Year Est. Return
+114.72%
3 Year Est. Return
+234.44%
5 Year Est. Return
+291.25%
10 Year Est. Return
+1,263.36%
AUM
$96.4B
AUM Growth
-$1.4B
(-1.4%)
Cap. Flow
+$1.2B
Cap. Flow
% of AUM
1.25%
Top 10 Holdings %
Top 10 Hldgs %
33.93%
Holding
280
New
10
Increased
138
Reduced
66
Closed
10
Avg Time Held
2.2
years
Top 10 Avg Time Held
2.4
years
Top 20 Avg Time Held
1.9
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AstraZeneca
AZN
|
+$363M |
| 2 |
JPMorgan Chase
JPM
|
+$363M |
| 3 |
American Airlines Group
AAL
|
+$310M |
| 4 |
CarMax
KMX
|
+$258M |
| 5 |
FedEx
FDX
|
+$191M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Johnson & Johnson
JNJ
|
+$779M |
| 2 |
DYAX
DYAX CORPORATION
DYAX
|
+$394M |
| 3 |
BRCM
BROADCOM CORP CL-A
BRCM
|
+$213M |
| 4 |
Bath & Body Works
BBWI
|
+$134M |
| 5 |
GSK
GSK
|
+$125M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 28.64% |
| 2 | Healthcare | 23.8% |
| 3 | Industrials | 15.3% |
| 4 | Consumer Discretionary | 9.55% |
| 5 | Financials | 7.33% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
151
DELISTED
Faro Technologies
FARO
| $58.7M | 0.06% |
1,821,742
+14,742
| +0.8% | +$412K |
2013 Q2
11 quarters
|
|
|
FEIC
152
DELISTED
FEI COMPANY
FEIC
| $58.6M | 0.06% |
657,800
-123,200
| -16% | -$9.53M |
2013 Q2
11 quarters
|
|
153
AbbVie
ABBV
$501B
| $58.4M | 0.06% |
1,022,845
-142,200
| -12% | -$7.93M |
2013 Q2
11 quarters
|
|
154
DELISTED
Novadaq Technologies Inc.
NVDQ
| $58.3M | 0.06% |
5,260,582
+279,502
| +6% | +$2.96M |
2014 Q4
5 quarters
|
|
155
Mastercard
MA
$540B
| $57.3M | 0.06% |
606,300
| – | – |
2013 Q2
11 quarters
|
|
156
Zimmer Biomet
ZBH
$18B
| $56.3M | 0.06% |
544,149
+824
| +0.2% | +$79.7K |
2013 Q2
11 quarters
|
|
|
SREV
157
DELISTED
ServiceSource International, Inc.
SREV
| $55.1M | 0.06% |
12,940,050
+2,340
| +0% | +$9.46K |
2014 Q1
8 quarters
|
|
158
Chegg
CHGG
$84.4M
| $51.7M | 0.05% |
11,581,990
+84,000
| +0.7% | +$426K |
2014 Q1
8 quarters
|
|
159
Edwards Lifesciences
EW
$50.8B
| $49.4M | 0.05% |
1,680,000
| – | – |
2013 Q2
11 quarters
|
|
160
Accuray
ARAY
$20.8M
| $49.4M | 0.05% |
8,544,500
-59,200
| -0.7% | -$328K |
2013 Q2
11 quarters
|
|
161
Herc Holdings
HRI
$4.15B
| $49M | 0.05% |
1,551,433
+21,833
| +1% | +$641K |
2013 Q2
11 quarters
|
|
162
Kirby Corp
KEX
$7.24B
| $47.8M | 0.05% |
792,395
+195,245
| +33% | +$10.6M |
2013 Q2
11 quarters
|
|
163
NOV
NOV
$6.64B
| $47.1M | 0.05% |
1,515,395
-5,700
| -0.4% | -$174K |
2013 Q2
11 quarters
|
|
164
Cerus
CERS
$455M
| $46.3M | 0.05% |
7,800,000
+300,000
| +4% | +$1.66M |
2015 Q1
4 quarters
|
|
165
DELISTED
Southwestern Energy Company
SWN
| $46.2M | 0.05% |
5,725,525
+122,200
| +2% | +$937K |
2013 Q2
11 quarters
|
|
166
PepsiCo
PEP
$175B
| $46.1M | 0.05% |
450,000
| – | – |
2013 Q2
11 quarters
|
|
167
Expeditors International
EXPD
$25.8B
| $45.9M | 0.05% |
939,400
-250,000
| -21% | -$11.5M |
2013 Q2
11 quarters
|
|
|
VA
168
DELISTED
Virgin America Inc.
VA
| $45.7M | 0.05% |
1,184,900
| – | – |
2015 Q1
4 quarters
|
|
|
169
GSK
GSK
$98.2B
| $45.3M | 0.05% |
893,508
-2,506,720
| -74% | -$125M |
2013 Q2
11 quarters
|
|
170
DELISTED
Spirit Airlines, Inc.
SAVE
| $44.3M | 0.05% |
924,324
-2,500
| -0.3% | -$112K |
2013 Q2
11 quarters
|
|
|
NUVA
171
DELISTED
NuVasive, Inc.
NUVA
| $43.8M | 0.05% |
901,000
| – | – |
2013 Q2
11 quarters
|
|
172
Axcelis
ACLS
$3.55B
| $38.7M | 0.04% |
3,452,300
+33,750
| +1% | +$345K |
2014 Q1
8 quarters
|
|
|
TUES
173
DELISTED
Tuesday Morning Corp
TUES
| $38.2M | 0.04% |
4,673,700
-607,850
| -12% | -$3.98M |
2013 Q2
11 quarters
|
|
174
American Express
AXP
$212B
| $35.3M | 0.04% |
574,700
| – | – |
2013 Q2
11 quarters
|
|
175
Norfolk Southern
NSC
$73B
| $34.8M | 0.04% |
417,662
-237,264
| -36% | -$17.9M |
2013 Q2
11 quarters
|
|
Similar funds
Primecap Management's Q1 2016 Portfolio in Review
As of Q1 2016, Primecap Management held 280 positions worth $96.4B, down 1.4% from $97.8B the previous quarter. Its ten largest holdings account for 34% of the portfolio.
Primecap Management's Q1 2016 filing shows 10 new, 138 increased, 66 reduced and 10 closed positions. Its largest new stake was Northern Trust: 1,775,400 shares worth $116M. The largest sale was Johnson & Johnson, an estimated $779M.
By sector, the portfolio is most concentrated in Technology at 29% of assets, up from 27% a quarter earlier, followed by Healthcare and Industrials.
- Primecap Management's largest Q1 2016 buy was Northern Trust: 1,775,400 shares worth $116M.
- Primecap Management added most to AstraZeneca in Q1 2016, an estimated $363M increase.
- Primecap Management's biggest Q1 2016 reduction was Johnson & Johnson, cutting an estimated $779M.
- Primecap Management fully exited DYAX CORPORATION in Q1 2016, selling an estimated $394M.
- Primecap Management's ten largest holdings make up 34% of its $96.4B portfolio in Q1 2016.
- Primecap Management opened 10 new positions and closed 10 in Q1 2016.
- Primecap Management's portfolio value fell 1.4% quarter-over-quarter to $96.4B.
Based on Primecap Management's 13F filing for Q1 2016, filed 12 May 2016.